Review Article| Volume 50, ISSUE 1, P1-17, February 2023

Approaches and Barriers to Biomarker Discovery

The Example of Biomarkers of Renal Scarring in Pediatric Urology


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Urologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shanon A.
        • et al.
        Evaluation of renal scars by technetium-labeled dimercaptosuccinic acid scan, intravenous urography, and ultrasonography: a comparative study.
        J Pediatr. 1992; 120: 399-403
        • Abdelhalim A.
        • Khoury A.E.
        Critical appraisal of the top-down approach for vesicoureteral reflux.
        Investig Clin Urol. 2017; 58: S14-S22
        • Herz D.
        • et al.
        5-year prospective results of dimercapto-succinic acid imaging in children with febrile urinary tract infection: proof that the top-down approach works.
        J Urol. 2010; 184: 1703-1709
        • Ward V.L.
        • et al.
        Pediatric radiation exposure and effective dose reduction during voiding cystourethrography.
        Radiology. 2008; 249: 1002-1009
        • Paolino J.
        • Treves S.T.
        Availability of (99m)Tc-DMSA.
        J Nucl Med. 2017; 58: 16N
        • Lim R.
        • Bar-Sever Z.
        • Treves S.T.
        Is Availability of (99m)Tc-DMSA insufficient to meet clinical needs in the United States? A Survey.
        J Nucl Med. 2019; 60: 14N-16N
        • Bramer W.M.
        • et al.
        De-duplication of database search results for systematic reviews in EndNote.
        J Med Libr Assoc. 2016; 104: 240-243
        • Zaffanello M.
        • et al.
        Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms.
        Pediatr Nephrol. 2011; 26: 1017-1029
        • Renata Y.
        • et al.
        Urinary concentration of cytokines in children with acute pyelonephritis.
        Eur J Pediatr. 2013; 172: 769-774
        • Tramma D.
        • et al.
        Interleukin-6 and interleukin-8 levels in the urine of children with renal scarring.
        Pediatr Nephrol. 2012; 27: 1525-1530
        • Tullus K.
        • et al.
        Urine interleukin-6 and interleukin-8 in children with acute pyelonephritis, in relation to DMSA scintigraphy in the acute phase and at 1-year follow-up.
        Pediatr Radiol. 1994; 24: 513-515
        • Sheu J.N.
        • et al.
        Relationship between serum and urine interleukin-6 elevations and renal scarring in children with acute pyelonephritis.
        Scand J Urol Nephrol. 2009; 43: 133-137
        • Gokce I.
        • et al.
        Urinary levels of interleukin-6 and interleukin-8 in patients with vesicoureteral reflux and renal parenchymal scar.
        Pediatr Nephrol. 2010; 25: 905-912
        • Sheu J.N.
        • et al.
        The role of serum and urine interleukin-8 on acute pyelonephritis and subsequent renal scarring in children.
        Pediatr Infect Dis J. 2009; 28: 885-890
        • Yavuz S.
        • Anarat A.
        • Bayazit A.K.
        Interleukin-18, CRP and procalcitonin levels in vesicoureteral reflux and reflux nephropathy.
        Ren Fail. 2013; 35: 1319-1322
        • Leroy S.
        • et al.
        Association of procalcitonin with acute pyelonephritis and renal scars in pediatric UTI.
        Pediatrics. 2013; 131: 870-879
        • Prat C.
        • et al.
        Elevated serum procalcitonin values correlate with renal scarring in children with urinary tract infection.
        Pediatr Infect Dis J. 2003; 22: 438-442
        • Belhadj-Tahar H.
        • et al.
        Procalcitonin implication in renal cell apoptosis induced by acute pyelonephritis in children.
        Infect Drug Resist. 2008; 1: 17-20
        • Bressan S.
        • et al.
        Procalcitonin as a predictor of renal scarring in infants and young children.
        Pediatr Nephrol. 2009; 24: 1199-1204
        • Sheu J.N.
        • et al.
        The role of procalcitonin for acute pyelonephritis and subsequent renal scarring in infants and young children.
        J Urol. 2011; 186: 2002-2008
        • Karavanaki K.
        • et al.
        Fever duration during treated urinary tract infections and development of permanent renal lesions.
        Arch Dis Child. 2019; 104: 466-470
        • Karavanaki K.A.
        • et al.
        Delayed treatment of the first febrile urinary tract infection in early childhood increased the risk of renal scarring.
        Acta Paediatr. 2017; 106: 149-154
        • Jakobsson B.
        • Berg U.
        • Svensson L.
        Renal scarring after acute pyelonephritis.
        Arch Dis Child. 1994; 70: 111-115
        • Byun H.J.
        • et al.
        The impact of obesity on febrile urinary tract infection and renal scarring in children with vesicoureteral reflux.
        J Pediatr Urol. 2017; 13: 67 e1-67 e6
        • Rodriguez L.M.
        • et al.
        Do serum C-reactive protein and interleukin-6 predict kidney scarring after urinary tract infection?.
        Indian J Pediatr. 2013; 80: 1002-1006
        • Stokland E.
        • et al.
        Renal damage one year after first urinary tract infection: role of dimercaptosuccinic acid scintigraphy.
        J Pediatr. 1996; 129: 815-820
        • Wang Y.T.
        • et al.
        Correlation of renal ultrasonographic findings with inflammatory volume from dimercaptosuccinic acid renal scans in children with acute pyelonephritis.
        J Urol. 2005; 173 ([discussion: 194]): 190-194
        • Swerkersson S.
        • et al.
        Relationship among vesicoureteral reflux, urinary tract infection and renal damage in children.
        J Urol. 2007; 178 ([discussion: 650-1]): 647-651
        • Kotoula A.
        • et al.
        Comparative efficacies of procalcitonin and conventional inflammatory markers for prediction of renal parenchymal inflammation in pediatric first urinary tract infection.
        Urology. 2009; 73: 782-786
        • Yilmaz I.
        • et al.
        Association of vesicoureteral reflux and renal scarring in urinary tract infections.
        Arch Argent Pediatr. 2018; 116: e542-e547
        • Liao P.F.
        • et al.
        Comparison of procalcitonin and different guidelines for first febrile urinary tract infection in children by imaging.
        Pediatr Nephrol. 2014; 29: 1567-1574
        • Kavukcu S.
        • et al.
        Serum vitamin A and beta-carotene concentrations and renal scarring in urinary tract infections.
        Arch Dis Child. 1998; 78: 271-272
        • Ohta N.
        • et al.
        Serum soluble ST2 as a marker of renal scar in pediatric upper urinary tract infection.
        Cytokine. 2019; 120: 258-263
        • Kitao T.
        • et al.
        Urinary Biomarkers for Screening for Renal Scarring in Children with Febrile Urinary Tract Infection: Pilot Study.
        J Urol. 2015; 194: 766-771
        • Rafiei A.
        • et al.
        Urinary neutrophil gelatinase-associated lipocalin (NGAL) might be an independent marker for anticipating scar formation in children with acute pyelonephritis.
        J Ren Inj Prev. 2015; 4: 39-44
        • Lee H.E.
        • et al.
        The diagnosis of febrile urinary tract infection in children may be facilitated by urinary biomarkers.
        Pediatr Nephrol. 2015; 30: 123-130
        • Yamanouchi S.
        • et al.
        Urinary C-megalin for screening of renal scarring in children after febrile urinary tract infection.
        Pediatr Res. 2018; 83: 662-668
        • Islekel H.
        • et al.
        Serum and urine cystatin C levels in children with post-pyelonephritic renal scarring: a pilot study.
        Int Urol Nephrol. 2007; 39: 1241-1250
        • Tullus K.
        • et al.
        Soluble receptors to tumour necrosis factor and interleukin-6 in urine during acute pyelonephritis.
        Acta Paediatr. 1997; 86: 1198-1202
        • Tullus K.
        • et al.
        Interleukin-1 alpha and interleukin-1 receptor antagonist in the urine of children with acute pyelonephritis and relation to renal scarring.
        Acta Paediatr. 1996; 85: 158-162
        • Abedi S.M.
        • et al.
        Urinary matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 biomarkers for predicting renal scar in children with urinary tract infection.
        Turk J Urol. 2017; 43: 536-542
        • Becerir T.
        • et al.
        Urinary excretion of pentraxin-3 correlates with the presence of renal scar following acute pyelonephritis in children.
        Int Urol Nephrol. 2019; 51: 571-577
        • Yilmaz A.
        • et al.
        Urine endothelin-1 levels as a predictor of renal scarring in children with urinary tract infections.
        Clin Nephrol. 2012; 77: 219-224
        • Sheu J.N.
        • et al.
        Urine interleukin-1beta in children with acute pyelonephritis and renal scarring.
        Nephrology (Carlton). 2007; 12: 487-493
        • Rafiei A.
        • et al.
        The urinary and serum levels of IL-32 in children with febrile urinary tract infections.
        Future Sci OA. 2017; 3: FSO242
        • Nishiwaki H.
        • et al.
        Urinary C-megalin as a novel biomarker of progression to microalbuminuria: a cohort study based on the diabetes Distress and Care Registry at Tenri (DDCRT 22).
        Diabetes Res Clin Pract. 2022; 186: 109810
        • Yildiz B.
        • et al.
        High sensitive C-reactive protein: a new marker for urinary tract infection, VUR and renal scar.
        Eur Rev Med Pharmacol Sci. 2013; 17: 2598-2604
        • Schoenborn J.R.
        • Wilson C.B.
        Regulation of interferon-gamma during innate and adaptive immune responses.
        Adv Immunol. 2007; 96: 41-101
        • Kaneko N.
        • et al.
        The role of interleukin-1 in general pathology.
        Inflamm Regen. 2019; 39: 12
        • Gadani S.P.
        • et al.
        IL-4 in the brain: a cytokine to remember.
        J Immunol. 2012; 189: 4213-4219
        • Mosser D.M.
        • Zhang X.
        Interleukin-10: new perspectives on an old cytokine.
        Immunol Rev. 2008; 226: 205-218
        • Chevalier R.L.
        The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.
        Am J Physiol Renal Physiol. 2016; 311: F145-F161
        • Kamijo A.
        • et al.
        Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules.
        Am J Pathol. 2004; 165: 1243-1255
        • Yoo J.J.
        • et al.
        The role of urinary N-Acetyl-beta-d-glucosaminidase in cirrhotic patients with acute kidney injury: multicenter, prospective cohort study.
        J Clin Med. 2021; 10: 4328
        • Gilbert R.E.
        • et al.
        Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology.
        Nephrol Dial Transpl. 2001; 16: 2442-2443
        • Drucker E.
        • Krapfenbauer K.
        Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine.
        EPMA J. 2013; 4: 7
        • Waerner T.
        • Thurnher D.
        • Krapfenbauer K.
        The role of laboratory medicine in healthcare: quality requirements of immunoassays, standardisation and data management in prospective medicine.
        EPMA J. 2010; 1: 619-626
        • Goh W.W.B.
        • Wang W.
        • Wong L.
        Why batch effects matter in omics data, and how to avoid them.
        Trends Biotechnol. 2017; 35: 498-507
        • Issaq H.J.
        • Waybright T.J.
        • Veenstra T.D.
        Cancer biomarker discovery: opportunities and pitfalls in analytical methods.
        Electrophoresis. 2011; 32: 967-975
        • Simon R.M.
        • Paik S.
        • Hayes D.F.
        Use of archived specimens in evaluation of prognostic and predictive biomarkers.
        J Natl Cancer Inst. 2009; 101: 1446-1452
        • Nygaard V.
        • Rodland E.A.
        • Hovig E.
        Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses.
        Biostatistics. 2016; 17: 29-39
        • Weaver V.M.
        • et al.
        Challenges for environmental epidemiology research: are biomarker concentrations altered by kidney function or urine concentration adjustment?.
        J Expo Sci Environ Epidemiol. 2016; 26: 1-8
        • Pepe M.S.
        • Li C.I.
        • Feng Z.
        Improving the quality of biomarker discovery research: the right samples and enough of them.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 944-950
        • Rodriguez H.
        • et al.
        Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics.
        Clin Chem. 2010; 56: 237-243
        • Regnier F.E.
        • et al.
        Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration.
        Clin Chem. 2010; 56: 165-171
        • Skates S.J.
        • et al.
        Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies.
        J Proteome Res. 2013; 12: 5383-5394
        • Soreide K.
        Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research.
        J Clin Pathol. 2009; 62: 1-5
        • Ioannidis J.P.
        Biomarker failures.
        Clin Chem. 2013; 59: 202-204
        • International Human Genome Sequencing, C
        Finishing the euchromatic sequence of the human genome.
        Nature. 2004; 431: 931-945
        • Wishart D.S.
        Metabolomics for investigating physiological and pathophysiological processes.
        Physiol Rev. 2019; 99: 1819-1875
        • Srivastava A.
        • Creek D.J.
        Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics.
        Proteomics. 2019; 19: e1700448
        • Crutchfield C.A.
        • et al.
        Advances in mass spectrometry-based clinical biomarker discovery.
        Clin Proteomics. 2016; 13: 1
        • Hawkridge A.M.
        • Muddiman D.C.
        Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality.
        Annu Rev Anal Chem (Palo Alto Calif). 2009; 2: 265-277
        • Zou W.
        • She J.
        • Tolstikov V.V.
        A comprehensive workflow of mass spectrometry-based untargeted metabolomics in cancer metabolic biomarker discovery using human plasma and urine.
        Metabolites. 2013; 3: 787-819
        • Seger C.
        • Salzmann L.
        After another decade: LC-MS/MS became routine in clinical diagnostics.
        Clin Biochem. 2020; 82: 2-11
        • Hasin Y.
        • Seldin M.
        • Lusis A.
        Multi-omics approaches to disease.
        Genome Biol. 2017; 18: 83
        • Tighe P.J.
        • et al.
        ELISA in the multiplex era: potentials and pitfalls.
        Proteomics Clin Appl. 2015; 9: 406-422
        • Pappireddi N.
        • Martin L.
        • Wuhr M.
        A review on quantitative multiplexed proteomics.
        Chembiochem. 2019; 20: 1210-1224
        • Rifai N.
        • Gillette M.A.
        • Carr S.A.
        Protein biomarker discovery and validation: the long and uncertain path to clinical utility.
        Nat Biotechnol. 2006; 24: 971-983
        • Boja E.
        • et al.
        Restructuring proteomics through verification.
        Biomark Med. 2010; 4: 799-803
        • Lopez Puga J.
        • Krzywinski M.
        • Altman N.
        Points of significance: Bayes' theorem.
        Nat Methods. 2015; 12: 277-278
      1. Python for the life sciences : a gentle introduction to Python for life scientistsz. Apress, Lancaster, Alexander ; Webster, Gordon. Berkeley, CA2019